CA2384059A1 - Method of treating cancer using tetraethyl thiuram disulfide - Google Patents
Method of treating cancer using tetraethyl thiuram disulfide Download PDFInfo
- Publication number
- CA2384059A1 CA2384059A1 CA002384059A CA2384059A CA2384059A1 CA 2384059 A1 CA2384059 A1 CA 2384059A1 CA 002384059 A CA002384059 A CA 002384059A CA 2384059 A CA2384059 A CA 2384059A CA 2384059 A1 CA2384059 A1 CA 2384059A1
- Authority
- CA
- Canada
- Prior art keywords
- thiuram disulfide
- administered
- cancer
- dosage
- heavy metal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y116/00—Oxidoreductases oxidizing metal ions (1.16)
- C12Y116/03—Oxidoreductases oxidizing metal ions (1.16) with oxygen as acceptor (1.16.3)
- C12Y116/03001—Ferroxidase (1.16.3.1), i.e. ceruloplasmin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
Abstract
Dithiocarbamate, particularly tetraethylthiuram disulfide strongly inhibits the growth of cancer cells of a variety of cell types. Such inhibitory effec t is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide t o reduce tumor growth, and to potentiate the effect of other anticancer agents .
Claims (53)
1 . A method for treating established cancer in a mammal comprising administering to said mammal a therapeutically effective amount of a thiuram disulfide and a heavy metal ion.
2. The method of Claim 1, wherein said thiuram disulfide is a tetraalkyl thiuram disulfide.
3. The method of Claim 1, wherein said tetraalkyl thiuram disulfide is tetraethyl thiuram disulfide.
4. The method of Claim 1, wherein said heavy metal ion is administered as a complex with said thiuram disulfide.
5. The method of Claim 1, wherein said heavy metal ion is selected from the group consisting of ions of arsenic, bismuth, cobalt, copper, chromium, gallium, gold, iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.
6. The method of Claim 1, wherein said heavy metal ion is selected from the group consisting of ions of gold, silver, and zinc.
7. The method of Claim 1, wherein said heavy metal ion is a copper ion.
8. The method of Claim 1, wherein the thiuram disulfide and the heavy metal ion are administered orally.
9. The method of Claim 1, wherein said thiuram disulfide and said heavy metal ion are administered intravenously.
10. The method of Claim 1, wherein said thiuram disulfide is administered a dosage of from about 125 to about 1000 mg.
11. The method of Claim 1, wherein the cancer is melanoma, lung cancer, breast cancer, or prostatic carcinoma.
12. The method of Claim 1, wherein said thiuram disulfide and said heavy metal ion are administered in combination with another anticancer agent.
13. The method of Claim 12, wherein said other anticancer agent is selected from group consisting of cisplatin, carboplatin, cyclophosphamide, nitrosoureas, fotemustine, herceptin, carmustine, vindesine, etoposide, daunorubicin, adriamycin, taxol, taxotere, fluorouracil, methotrexate, melphalan, bleomycin, salicylates, aspirin, piroxicam, ibuprofen, indomethacin, maprosyn, diclofenac, tolmetin, ketoprofen, nabumetone, oxaprozin, and doxirubincin.
14. The method of Claim 12, wherein said other anticancer agent is cisplatin or carmustine.
15. A method for treating in human established cancer selected from the group consisting of melanoma, lung cancer, breast cancer, and prostatic carcinoma, said method comprising administering to said human a complex of tetraethyl thiuram disulfide and copper ion at a dosage of from about 125 to about 1000 mg.
16. A method for treating established cancer in a mammal comprising administering to said mammal a therapeutically effective amount of a thiuram disulfide and a cytokine selected from the group consisting of interferon .alpha., interferon .beta., interferon .gamma., and IL-6.
17. The method of Claim 16, wherein said thiuram disulfide is a tetraalkyl thiuram disulfide.
18. The method of Claim 16, wherein said thiuram disulfide is tetraethyl thiuram disulfide.
19. The method of Claim 16, wherein said thiuram disulfide is administered orally.
20. The method of Claim 16, wherein said thiuram disulfide and said cytokine are administered intravenously.
21. The method of Claim 16, wherein said thiuram disulfide is administered a dosage of from about 125 to about 1000 mg.
22. The method of Claim 16, wherein said IL-6 is administered at a dosage of from about 1 to about 100 mg/Kg per day.
23. The method of Claim 16, wherein the interferon .alpha. is administered at a dosage of about 3 x 10 6 to 8 x 10 6 international units per day.
24. The method of Claim 16, wherein the interferon .beta. is administered at a dosage of from about 15 to about 60 µg per day.
25. The method of Claim 16, wherein the interferon .gamma. is administered at a dosage of from about 50 to about 250 µg per day.
26. The method of Claim 16, wherein the cancer is melanoma, lung cancer, breast cancer, or prostatic carcinoma.
27. The method of Claim 16, further comprising administering to said mammal a therapeutically effective amount of another anticancer agent.
28. The method of Claim 27, wherein said other anticancer agent is selected from group consisting of cisplatin, carboplatin, cyclophosphamide, nitrosoureas, fotemustine, herceptin, carmustine, vindesine, etoposide, daunorubicin, adriamycin, taxol, taxotere, fluorouracil, methotrexate, melphalan, bleomycin, salicylates, aspirin, piroxicam, ibuprofen, indomethacin, maprosyn, diclofenac, tolmetin, ketoprofen, nabumetone, oxaprozin, and doxirubincin.
29. The method of Claim 27, wherein the other anticancer agent is cisplatin or carmustine.
30. A method for treating established cancer in a mammal comprising administering to said mammal a therapeutically effective amount of a thiuram disulfide and ceruloplasmin.
31. The method of Claim 30, wherein said thiuram disulfide is a tetraalkyl thiuram disulfide.
32. The method of Claim 31, wherein said tetraalkyl thiuram disulfide is tetraethyl thiuram disulfide.
33. The method of Claim 30, wherein said thiuram disulfide is administered orally.
34. The method of Claim 30, wherein said thiuram disulfide and said ceruloplasmin are administered intravenously.
35. The method of Claim 30, wherein said thiuram disulfide is administered a dosage of from about 125 to about 1000 mg.
36. The method of Claim 30, wherein said ceruloplasmin is administered at a dosage of from about 5 to about 30 mg per day.
37. The method of Claim 30, wherein the established cancer is melanoma, lung cancer, breast cancer, or prostatic carcinoma.
38. The method of Claim 30, further comprising administering to the mammal a therapeutically effective amount of another anticancer agent.
39. The method of Claim 38, where the other anticancer agent is ciplatin or carmustine.
40. A method for treating an established cancer of melanoma, lung cancer, breast cancer, or prostatic carcinoma in a human, comprising administering to said human tetraethyl thiuram disulfide at a dosage of from about 125 to about 1000 mg, and ceruloplasmin at an amount of from about 5 to about 30 mg per day.
41. A method for treating established cancer in a mammal comprising administering to said mammal a therapeutically active amount of a thiuram disulfide.
42. The method according to Claim 41, wherein the established cancer is melanoma, lung cancer, breast cancer, or prostatic carcinoma.
43. The method of Claim 41, wherein said thiuram disulfide is a tetraalkyl thiuram disulfide.
44. The method of Claim 41, wherein said thiuram disulfide is tetraethyl thiuram disulfide.
45. The method of Claim 41, wherein said tetraethyl thiuram disulfide is administered at a dosage of from about 125 to about 1000 mg.
46. The method of Claim 41, wherein said thiuram disulfide is administered orally.
47. The method of Claim 41, wherein said thiuram disulfide is administered in combination with another anticancer agent.
48. A method for treating an established cancer in human selected from the group consisting of melanoma, lung cancer, breast cancer, and prostatic carcinoma, said method comprising administering to said human tetraethyl thiuram disulfide at a dosage of from about 125 to about 1000 mg.
49. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and a complex between a thiuram disulfide and a heavy metal ion.
50. The pharmaceutical composition of Claim 49, wherein said thiuram disulfide is tetraethyl thiuram disulfide.
51. The composition of Claim 49, wherein said heavy metal ion is selected from the group consisting of gold, silver, selenium and zinc ions.
52. The composition of Claim 49, wherein said heavy metal ion is a copper ion.
53. The composition of Claim 49, further comprising another anticancer agent.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/392,122 | 1999-09-08 | ||
US09/392,122 US6589987B2 (en) | 1998-09-08 | 1999-09-08 | Method of treating cancer using tetraethyl thiuram disulfide |
PCT/US1999/027193 WO2001017522A1 (en) | 1999-09-08 | 1999-11-15 | Method of treating cancer using tetraethyl thiuram disulfide |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2384059A1 true CA2384059A1 (en) | 2001-03-15 |
CA2384059C CA2384059C (en) | 2010-06-22 |
Family
ID=23549328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2384059A Expired - Lifetime CA2384059C (en) | 1999-09-08 | 1999-11-15 | Method of treating cancer using tetraethyl thiuram disulfide |
Country Status (9)
Country | Link |
---|---|
US (1) | US6589987B2 (en) |
EP (1) | EP1214063B1 (en) |
JP (1) | JP2003514769A (en) |
AT (1) | ATE300291T1 (en) |
AU (1) | AU782029B2 (en) |
CA (1) | CA2384059C (en) |
DE (1) | DE69926407T2 (en) |
ES (1) | ES2244237T3 (en) |
WO (1) | WO2001017522A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7816403B2 (en) | 1998-09-08 | 2010-10-19 | University Of Utah Research Foundation | Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548540B2 (en) * | 1998-09-08 | 2003-04-15 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using dithiocarbamate derivatives |
AU2002226650A1 (en) * | 2001-01-18 | 2002-07-30 | Arnold Hoffman | Redox therapy for tumors |
US20030073609A1 (en) * | 2001-06-29 | 2003-04-17 | Pinkerton Thomas C. | Enhanced pharmacokinetic profile of intradermally delivered substances |
US7638331B2 (en) | 2004-01-02 | 2009-12-29 | The Administration of the Tulane Rducation Fund | Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery |
WO2006104396A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Pre-complexed copper antagonist compositions |
WO2008068746A2 (en) * | 2006-12-04 | 2008-06-12 | Yeda Research And Development Co. Ltd. | Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders |
EP2101567A4 (en) | 2007-01-18 | 2010-04-21 | Univ Utah Res Found | Compositions and methods for detecting, treating, or preventing reductive stress |
US20110206756A1 (en) * | 2008-03-17 | 2011-08-25 | University Of Utah Research Foundation | Dithiocarbamate metal chelates and methods of making and using thereof |
GB201020860D0 (en) * | 2010-12-09 | 2011-01-26 | Univ Wolverhampton | Disulfiram formulation and uses thereof |
US10369108B2 (en) | 2013-03-15 | 2019-08-06 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
EP3079668A1 (en) | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
WO2017049529A1 (en) | 2015-09-24 | 2017-03-30 | Innolife Co., Ltd. | A pharmaceutical composition comprising a copper chelating tetramine and the use thereof |
EP3311843A1 (en) * | 2016-10-13 | 2018-04-25 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Compositions comprising dithiocarbamate and cyclodextrin |
US10322096B2 (en) | 2016-10-26 | 2019-06-18 | Cantex Pharmaceuticals, Inc. | Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms |
ES2877149T3 (en) * | 2017-09-26 | 2021-11-16 | Palacky Univ In Olomouc | Bioavailable metal-dithiocarbamate complex nanoparticles, method of preparation and use thereof |
KR20190056758A (en) | 2017-11-17 | 2019-05-27 | 주식회사 지뉴브 | Combination therapy for treating cancers characterized by having cancer stem cells |
EP3693740A1 (en) * | 2019-02-07 | 2020-08-12 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Improved dithiocarmabate based compounds, therapies and diagnostics |
CN111135175B (en) * | 2020-01-17 | 2022-09-16 | 中国医学科学院放射医学研究所 | Application of DSF-2 in preparing anti-tumor and anti-radiation medicines |
WO2021257880A1 (en) * | 2020-06-18 | 2021-12-23 | Spring Discovery, Inc. | Use of aldh modulators or gasdermin d inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system |
US11351128B1 (en) * | 2021-05-13 | 2022-06-07 | Lance L. Gooberman | Pharmaceutical compositions and methods of administration |
CN114010624B (en) * | 2021-12-13 | 2023-03-28 | 上海纳米技术及应用国家工程研究中心有限公司 | Application of disulfiram and methotrexate in preparation of anti-liver cancer drugs |
WO2024046332A1 (en) * | 2022-08-29 | 2024-03-07 | 石贵中 | Pharmaceutical composition and use thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4148885A (en) | 1973-09-25 | 1979-04-10 | Institut Merieux | Immunostimulant medicine |
US4594238A (en) | 1980-08-08 | 1986-06-10 | Regents Of University Of Minnesota | Inhibition of undesired effect of platinum compounds |
US4426372A (en) | 1980-08-08 | 1984-01-17 | Regents Of The University Of Minnesota | Inhibition of undesired effects of platinum(II) compounds |
US4581224A (en) | 1980-08-08 | 1986-04-08 | Regents Of The University Of Minnesota | Inhibition of undesired effect of platinum compounds |
US4762705A (en) | 1981-11-10 | 1988-08-09 | Adolf W. Schwimmer | Cancer therapy with interferon |
US4645661A (en) | 1984-06-29 | 1987-02-24 | St. Jude Children's Research Hospital | Method for alleviating cisplatin-induced nephrotoxicity and dithiocarbamate compounds for effecting same |
US5187193A (en) | 1988-09-12 | 1993-02-16 | University Of Rochester | Method for stimulating transplanted bone marrow cells |
US5035878A (en) | 1988-09-12 | 1991-07-30 | University Of Rochester | Use of dithiocarbamates to counteract myelosuppression |
JPH04202139A (en) | 1990-11-30 | 1992-07-22 | Tosoh Corp | Vascularization suppressing agent |
ATE168014T1 (en) | 1991-11-08 | 1998-07-15 | Somatogen Inc | HEMOGLOBINS AS A DRUG DELIVERY SYSTEM |
US5807884A (en) | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5380747A (en) | 1992-10-30 | 1995-01-10 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5783596A (en) | 1992-10-30 | 1998-07-21 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5786344A (en) | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
US5792787A (en) | 1995-06-07 | 1998-08-11 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
EP0996440A1 (en) | 1996-11-06 | 2000-05-03 | Morris D. Faiman | Method for treatment of glutamate related disorders |
IL122891A0 (en) | 1998-01-11 | 1998-08-16 | Yeda Res & Dev | Pharmaceutical compositions comprising a thiocarbamate |
IL122892A0 (en) | 1998-01-11 | 1998-08-16 | Yeda Res & Dev | Pharmaceutical compositions comprising a thiocarbamate |
-
1999
- 1999-09-08 US US09/392,122 patent/US6589987B2/en not_active Expired - Lifetime
- 1999-11-15 JP JP2001521313A patent/JP2003514769A/en active Pending
- 1999-11-15 DE DE69926407T patent/DE69926407T2/en not_active Expired - Lifetime
- 1999-11-15 CA CA2384059A patent/CA2384059C/en not_active Expired - Lifetime
- 1999-11-15 WO PCT/US1999/027193 patent/WO2001017522A1/en active IP Right Grant
- 1999-11-15 AU AU20255/00A patent/AU782029B2/en not_active Expired
- 1999-11-15 AT AT99963914T patent/ATE300291T1/en not_active IP Right Cessation
- 1999-11-15 EP EP99963914A patent/EP1214063B1/en not_active Expired - Lifetime
- 1999-11-15 ES ES99963914T patent/ES2244237T3/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7816403B2 (en) | 1998-09-08 | 2010-10-19 | University Of Utah Research Foundation | Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same |
Also Published As
Publication number | Publication date |
---|---|
JP2003514769A (en) | 2003-04-22 |
ATE300291T1 (en) | 2005-08-15 |
ES2244237T3 (en) | 2005-12-01 |
AU782029B2 (en) | 2005-06-30 |
AU2025500A (en) | 2001-04-10 |
EP1214063A1 (en) | 2002-06-19 |
US6589987B2 (en) | 2003-07-08 |
DE69926407T2 (en) | 2006-05-24 |
WO2001017522A1 (en) | 2001-03-15 |
US20030065026A1 (en) | 2003-04-03 |
DE69926407D1 (en) | 2005-09-01 |
CA2384059C (en) | 2010-06-22 |
EP1214063B1 (en) | 2005-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2384059A1 (en) | Method of treating cancer using tetraethyl thiuram disulfide | |
Oronsky et al. | A review of clinical radioprotection and chemoprotection for oral mucositis | |
Hu et al. | Arsenic in cancer therapy | |
Reiffers et al. | Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases | |
Scully et al. | Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis | |
Salem et al. | Cis‐diamminedichloroplatinum (II) by 5‐day continuous infusion a new dose schedule with minimal toxicity | |
Scheulen et al. | Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients | |
Gore et al. | High dose carboplatin in the treatment of lung cancer and mesotherlioma: A phase I dose escalation study | |
Amadori et al. | Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent | |
Tandon et al. | Oxidative stress: a novel strategy in cancer treatment | |
JP2004529104A5 (en) | ||
RU2008138560A (en) | IMPROVED METHODS FOR TREATING TUMORS | |
Ludwig | Epoetin in cancer-related anaemia. | |
US20060008535A1 (en) | Anti tumor compositions and methods of use | |
US20080081051A1 (en) | Method of manufacturing anti-tumor and anti-viral compositions | |
JP2004535441A5 (en) | ||
IL300151A (en) | Combinations for the treatment of cancer | |
Biswal | Current trends in the management of oral mucositis related to cancer treatment | |
Ibrahim et al. | High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients. A pilot study | |
Alberola et al. | Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer | |
Amorino et al. | Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy | |
CN111989092A (en) | Combination therapy of BET inhibitors and proteasome inhibitors | |
RU2009134479A (en) | CCI-779 ANTI-TUMOR ACTIVITY IN PAPILLARY RENAL CELL CELL CANCER | |
Vey | Arsenic trioxide for the treatment of myelodysplastic syndromes | |
Elliott et al. | Chemotherapy with [SP-4-3-(R)]-[1, 1-cyclobutanedicarboxylato (2-)](2-methyl-1, 4-butanediamine-N, N′) platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20191115 |